Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity

S. Koloszar, Z. Pal, A. Kereszturi, G. Vajda, A. Pál, J. Daru

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The aromatase inhibitor anastrazole proved effective in the treatment of endometrial hyperplasia and postmenopausal bleeding in an obese 65-year-old woman with high operative risk. During anastrazole administration for 12 months, the endometrial thickness decreased from 9.8 mm to 2.4 mm and the control endometrial histology showed an atrophic endometrium. Uterine bleeding did not occur in the post-treatment, 3-year follow-up period. The endometrial thicknesses measured yearly by ultrasonography were 2.9, 3.5 and 3.3 mm. The plasma estradiol levels increased from <73 pmol/l post-treatment to 112, 98 and 103 pmol/l. This case demonstrates that long-term aromatase inhibitor treatment can result in a refractory status of the endometrium and the estradiol produced in the adipose tissue does not exert a proliferative effect.

Original languageEnglish
Pages (from-to)93-94
Number of pages2
JournalClimacteric
Volume15
Issue number1
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Aromatase Inhibitors
Hyperplasia
Obesity
Endometrium
Estradiol
Endometrial Hyperplasia
Uterine Hemorrhage
Therapeutics
Adipose Tissue
Ultrasonography
Histology
Hemorrhage
anastrozole

Keywords

  • aromatase inhibitor treatment
  • Endometrial hyperplasia
  • long-term effect
  • menopause
  • obesity

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity. / Koloszar, S.; Pal, Z.; Kereszturi, A.; Vajda, G.; Pál, A.; Daru, J.

In: Climacteric, Vol. 15, No. 1, 02.2012, p. 93-94.

Research output: Contribution to journalArticle

Koloszar, S, Pal, Z, Kereszturi, A, Vajda, G, Pál, A & Daru, J 2012, 'Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity', Climacteric, vol. 15, no. 1, pp. 93-94. https://doi.org/10.3109/13697137.2011.604143
Koloszar, S. ; Pal, Z. ; Kereszturi, A. ; Vajda, G. ; Pál, A. ; Daru, J. / Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity. In: Climacteric. 2012 ; Vol. 15, No. 1. pp. 93-94.
@article{09598eae33014288981f41585285c76f,
title = "Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity",
abstract = "The aromatase inhibitor anastrazole proved effective in the treatment of endometrial hyperplasia and postmenopausal bleeding in an obese 65-year-old woman with high operative risk. During anastrazole administration for 12 months, the endometrial thickness decreased from 9.8 mm to 2.4 mm and the control endometrial histology showed an atrophic endometrium. Uterine bleeding did not occur in the post-treatment, 3-year follow-up period. The endometrial thicknesses measured yearly by ultrasonography were 2.9, 3.5 and 3.3 mm. The plasma estradiol levels increased from <73 pmol/l post-treatment to 112, 98 and 103 pmol/l. This case demonstrates that long-term aromatase inhibitor treatment can result in a refractory status of the endometrium and the estradiol produced in the adipose tissue does not exert a proliferative effect.",
keywords = "aromatase inhibitor treatment, Endometrial hyperplasia, long-term effect, menopause, obesity",
author = "S. Koloszar and Z. Pal and A. Kereszturi and G. Vajda and A. P{\'a}l and J. Daru",
year = "2012",
month = "2",
doi = "10.3109/13697137.2011.604143",
language = "English",
volume = "15",
pages = "93--94",
journal = "Climacteric",
issn = "1369-7137",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Effects of aromatase inhibitor on menopausal hyperplasia in a case of obesity

AU - Koloszar, S.

AU - Pal, Z.

AU - Kereszturi, A.

AU - Vajda, G.

AU - Pál, A.

AU - Daru, J.

PY - 2012/2

Y1 - 2012/2

N2 - The aromatase inhibitor anastrazole proved effective in the treatment of endometrial hyperplasia and postmenopausal bleeding in an obese 65-year-old woman with high operative risk. During anastrazole administration for 12 months, the endometrial thickness decreased from 9.8 mm to 2.4 mm and the control endometrial histology showed an atrophic endometrium. Uterine bleeding did not occur in the post-treatment, 3-year follow-up period. The endometrial thicknesses measured yearly by ultrasonography were 2.9, 3.5 and 3.3 mm. The plasma estradiol levels increased from <73 pmol/l post-treatment to 112, 98 and 103 pmol/l. This case demonstrates that long-term aromatase inhibitor treatment can result in a refractory status of the endometrium and the estradiol produced in the adipose tissue does not exert a proliferative effect.

AB - The aromatase inhibitor anastrazole proved effective in the treatment of endometrial hyperplasia and postmenopausal bleeding in an obese 65-year-old woman with high operative risk. During anastrazole administration for 12 months, the endometrial thickness decreased from 9.8 mm to 2.4 mm and the control endometrial histology showed an atrophic endometrium. Uterine bleeding did not occur in the post-treatment, 3-year follow-up period. The endometrial thicknesses measured yearly by ultrasonography were 2.9, 3.5 and 3.3 mm. The plasma estradiol levels increased from <73 pmol/l post-treatment to 112, 98 and 103 pmol/l. This case demonstrates that long-term aromatase inhibitor treatment can result in a refractory status of the endometrium and the estradiol produced in the adipose tissue does not exert a proliferative effect.

KW - aromatase inhibitor treatment

KW - Endometrial hyperplasia

KW - long-term effect

KW - menopause

KW - obesity

UR - http://www.scopus.com/inward/record.url?scp=84855218867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855218867&partnerID=8YFLogxK

U2 - 10.3109/13697137.2011.604143

DO - 10.3109/13697137.2011.604143

M3 - Article

C2 - 22132829

AN - SCOPUS:84855218867

VL - 15

SP - 93

EP - 94

JO - Climacteric

JF - Climacteric

SN - 1369-7137

IS - 1

ER -